53,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
27 °P sammeln
  • Broschiertes Buch

The book describes the effort undertaken by the author for developing some potential radiopharmaceuticals during the course of his Ph.D. work carried out at the Radiopharmaceuticals Division of Bhabha Atomic Research Centre, Mumbai, India. The book consists of four chapters. The first chapter briefly describes the different aspects related to radiopharmaceutical sciences. In the second chapter, development of three potential radiopharmaceuticals which could find use in liquid-filled balloons as IVRT agents has been described. Third chapter describes the development of two potential…mehr

Produktbeschreibung
The book describes the effort undertaken by the author for developing some potential radiopharmaceuticals during the course of his Ph.D. work carried out at the Radiopharmaceuticals Division of Bhabha Atomic Research Centre, Mumbai, India. The book consists of four chapters. The first chapter briefly describes the different aspects related to radiopharmaceutical sciences. In the second chapter, development of three potential radiopharmaceuticals which could find use in liquid-filled balloons as IVRT agents has been described. Third chapter describes the development of two potential tumor-specific agents - one for the imaging of hypoxia tumors while the other one is for targeted tumor therapy. Last chapter deals with the development of two receptor-specific agents - one has the potential for imaging tumors over-expressing androgen receptors while the other for targeted therapy of tumors which over-express estrogen receptors. This chapter also describes the excellent potential of 177Lu, which may become one of the most important therapeutic radionuclide in the near future.
Autorenporträt
Tapas did his post-graduation in Chemistry from 'University of Kalyani', West Bengal, India and joined 'Radiopharmaceuticals Division' of India's prestigious research institute 'Bhabha Atomic Research Centre' as Scientific Officer in 1998. His field of research interest includes production of radioisotopes and development of radiopharmaceuticals.